ViaCyte clinical trials

Acquired by Vertex Pharmaceuticals Incorporated, Sep 27, 2022 · source ↗

The registry lists 5 studies whose lead sponsor is ViaCyte. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 3, 2024.

Before and after it joined Vertex Pharmaceuticals Incorporated

First submitted before ViaCyte became part of Vertex Pharmaceuticals Incorporated: 5
First submitted after ViaCyte became part of Vertex Pharmaceuticals Incorporated: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 3
Terminated: 2

Phase

Phase 1: 4
Phase 2: 3

Where

United States: 3
Canada: 3
Belgium: 1

Registry sponsor names on this page

ViaCyte5 studies

Something wrong with this grouping? Tell us on the Vertex Pharmaceuticals Incorporated page.

Studies

Recruiting first, then most recently updated. Showing 5 of 5. All Vertex Pharmaceuticals Incorporated studies →

A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia UnawarenessCompletedNCT03163511Phase 1/2
Sponsor listed in the registry: ViaCyte · First submitted before ViaCyte became part of Vertex Pharmaceuticals Incorporated
One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™CompletedNCT02939118
Sponsor listed in the registry: ViaCyte · First submitted before ViaCyte became part of Vertex Pharmaceuticals Incorporated
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes MellitusTerminatedNCT04678557Phase 1/2
Sponsor listed in the registry: ViaCyte · First submitted before ViaCyte became part of Vertex Pharmaceuticals Incorporated
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes MellitusTerminatedNCT02239354Phase 1/2
Sponsor listed in the registry: ViaCyte · First submitted before ViaCyte became part of Vertex Pharmaceuticals Incorporated
A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes MellitusCompletedNCT03162926Phase 1
Sponsor listed in the registry: ViaCyte · First submitted before ViaCyte became part of Vertex Pharmaceuticals Incorporated